EP0489113A1 - Verwendung von thioredoxin in der behandlung bösartig transformierter zellen bei tieren und beim menschen - Google Patents

Verwendung von thioredoxin in der behandlung bösartig transformierter zellen bei tieren und beim menschen

Info

Publication number
EP0489113A1
EP0489113A1 EP90913906A EP90913906A EP0489113A1 EP 0489113 A1 EP0489113 A1 EP 0489113A1 EP 90913906 A EP90913906 A EP 90913906A EP 90913906 A EP90913906 A EP 90913906A EP 0489113 A1 EP0489113 A1 EP 0489113A1
Authority
EP
European Patent Office
Prior art keywords
thioredoxin
treatment
factor
cells
transformed cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90913906A
Other languages
English (en)
French (fr)
Inventor
Anders Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of EP0489113A1 publication Critical patent/EP0489113A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Definitions

  • thioredoxin in the treatment of malignantly transformed cells in animals and man.
  • the present invention relates to a novel strategy for the treatment of B lymphocyte leukemias and certain other malignant diseases, including a method for potentiating the reactivity of lymphocytes responsive towards cancer cells expressing surface structures recognized by the patient's own cytotoxic cells.
  • cancers are malignant melanomas and colon cancer.
  • B-cell growth factors and antibodies that mimic these, can be used for the induction of differentiation in certain malignant disorders.
  • an enzyme belonging to the thioredoxin family such as MP6 cell line derived thioredoxin (MP6/Trx) for such induction of differentiation.
  • MP6/Trx MP6 cell line derived thioredoxin
  • Cancer cells are characterized by uncontrolled growth. For some time there has been a concept that growth can be suppressed by inducing these cells to differentiate into a non proliferative state. Clinical trials have also been done in different leukemias with differentiation-inducing agents such as vitamins and interferons. However, no such trials have been done with more specific growth and differentiation factors, or antibodies, which only react with defined receptor structures. The present invention proposes to use such specific factors for cancer treatment, either alone or in combination with supporting, agents. The development of normal cells into cancer cells is a multi-step process. During malignant transformation some cell types, for example some B lymphocytes (reference 1), acquire the ability to express receptors for defined growth factors and respond to these by proliferation or maturation.
  • B lymphocytes reference 1
  • the tumor cells are thus "frozen” at a speci ⁇ fic differentiation stage, characterized by a specific set of surface receptors.
  • This block is, however, not irreversible.
  • the said enzyme and co-factors are described.
  • B-CLL B-cell chronic lymphocytic leukemias
  • the initial activation signal elicited by the antigen - immunoglobulin (Ig) interaction
  • the initial activation signal must be followed by a series of finely tuned receptor- ligand signals and cell-cell interactions with other immunocompetent cells (1) , to allow terminal plasma cell maturation.
  • Several ligands for receptors involved in the transmission of growth and differentiation controlling signals in human B cells have been defined and the genes cloned. These include interleukin 1 (IL-1) to interleukin 6 (IL-6), low molecular weight B cell growth factor (LMW- BCGF) , sCD23, lymphotoxin (LT) , tumor necrosis factor (TNF), interferon-£ (IFN-tf) (1,2).
  • the activation step where the cells are exposed to activating factors.
  • activating factors include Antigens; anti-immunoglobulins (anti-idiotypes) ; interleukin 1, 2 and 3 and sub-components thereof, interleukin 4 (IL4) and antibodies to the IL4-receptor; reagents acting on the C3d-receptor (CDllc), such as polymerized complement 3d or antibodies to the C3d receptor (anti-gpl40) ; anti-gp35 (CD20).
  • Phorbol esters, such as TPA or PMA are used experimentally in vitro as potent competence-inducing agents, but these can however only serve as models since they are toxic and incompatible with clinical use.
  • the phorbol esters act on protein kinase C (PKC) and in their function mimic biologically active agents.
  • PPC protein kinase C
  • Other experimental competence-inducing agents of importance are: solid phase protein-A; inactivated Staphylococcus Aureus Cowan I (SAC); Poke-weed Mitogen (PWM) ; non-transforming or inactivated Epstein- Barr Virus (EBV) (from the non-transforming strain P3HR1 or UV-inactivated virus) lipopolysaccharides (LPS) .
  • the progression step induces receptors for various progression signals such as : IL-2; B-cell growth factor II or TRF, now called IL5; low molecular weight BCGF (12K BCGF); Namalwa-derived 60K BCGF; antibodies to CD23 (a p45 protein expressed on the B-cell surface of IgM+, IgD+ cells, FcE receptor 2 (FcER2) antibodies to CD40, a p50 antigen present mainly on B- cells and on urinary bladder carcinoma cells, but also on cervical and lung carcinoma cells, furthermore IL-6 (previously called B-cell differentiation factor (BCDF).
  • BCDF B-cell differentiation factor
  • BCDF B-cell differentiation factor
  • BCGF B-cell growth factor
  • B-CLL B-cell chronic lymphocytic leukemia
  • BSF B-cell stimulating factor
  • CD23 A p45 protein expressed on cells of the B- lymphocyte linage
  • CD40 A p50 protein expressed on B-cells and on bladder carcinoma cells
  • EBV Epstein-Barr virus
  • gp35 Glycoprotein 35K molecular weight, belonging to the CD20 group (cluster of differentiation group)
  • gpl40 Glycoprotein 14OK molecular weight, with C3d- receptor function
  • IgD Immunoglobulin class D
  • IgM Immunoglobulin class M IL-1, IL-2, IL-3, IL-4, IL-5: Interleukin 1, 2, 3, 4, 5
  • Molt4 A T-lymphoma derived cell line p45 A 45K molecular weight membrane protein
  • TPA Tumor promoting agent
  • TRF T-cell replacing factor
  • T-T hybridoma A somatic cell hybrid between two different T-cells.
  • MP6/Trx MP6 T-T hybridoma cell line produced enzyme of thioredoxin family.
  • BSF B cell stimulatory factor
  • MP Thioredoxin is a well-characterized enzyme catalyzing thiol disulphide interchange reactions and net protein disulphide reductions via a Cys-Gly-Pro-Cys active site.
  • MP Thioredoxin is a well-characterized enzyme catalyzing thiol disulphide interchange reactions and net protein disulphide reductions via a Cys-Gly-Pro-Cys active site.
  • monoclonal B cells, B- lymphoblastoid cell lines, or B cells derived from B-type o chronic lymphocytic leukemia (B-C L) were target cells par excellence, since they required MP6/Trx for cytokine induce proliferation and differentiation in vitro, when tested unde suboptimal cell culture conditions.
  • Pre-activated cells did proliferate in response to the recombinant or natural ligands: interleukin 2 (IL-2), interleukin 4 (IL 4), low molecular weight BCGF (LMW- BCGF), tumor necrosis factor- ⁇ , (T F- ⁇ ), or anti-CD40, only if MP6/Trx was added.
  • IL-2 interleukin 2
  • IL 4 interleukin 4
  • LMW- BCGF low molecular weight BCGF
  • T F- ⁇ tumor necrosis factor- ⁇
  • anti-CD40 anti-CD40
  • the present invention relates to a novel method for the treatment of such malignantly transformed cells in mammals and in man, which are sensitive to the co-factors mentioned below and to thioredoxin.
  • the method is characterized by the administration of a therapeutically adequate amount of thioredoxin. If necessary, said enzyme is administered following a period of pre-treatment with a co-factor capable of inducing the malignantly transformed cells to become sensitive to said enzyme.
  • co-factors are given in Table 1 below. It is foreseen that the administration of the enzyme thioredoxin can be made simultaneously with the co-factor.
  • thioredoxin as used in the present specification is understood to include the thioredoxin enzyme family and analogues of thioredoxin containing the active site Cys-Gly-Pro-Cys, specifically the MP6 cell line-derived thioredoxin.
  • the novel method of treatment by the present invention can be applied to stem-cell disorders, hematopoetic malignancies, for example leukemias, B-cell leukemias and B-cell chronic lymphocytic leukemias, and other tumors which express co-factor receptors and respond to thioredoxin.
  • bladder carcinomas expressing the CD40 antigen can potentially be treated in the described fashion.
  • Thioredoxin as well as the co-factors listed in Table 1 are substances which are known as such. They are, however, not in every instance known to have therapeutic utility.
  • the choice of a suitable co-factor is no critical parameter of the invention. There are experimental methods available which will enable the skilled worker to establish whether a specific co-factor as listed in Table 1 acts in synergy with the thioredoxin. It is, however, preferred to use IL-2 as co-factor. Also IL-4 and TNF-od may be mentioned as preferred co-factors.
  • the invention in another aspect relates to thioredoxin for use in the treatment of malignantly transformed cells in animals and in man, in particular for use in such malignantly transformed cells which are sensitive to thioredoxin.
  • thioredoxin is administered following a period of pre- treatment with a co-factor as described, which is capable of inducing the malignantly transformed cells to develop sensitivity for thioredoxin.
  • Another aspect of the invention relates to the use of thioredoxin in the preparation of a medicament for treatment of malignancies.
  • a medicament may comprise a co-factor as described above.
  • thioredoxin as well as co-factors as exemplified in Table 1 are known in the art, pharma ⁇ ceutical preparations containing thioredoxin or of a combination of thioredoxin and a co-factor according to Table 1, are novel and represent as such an additional aspect of the present invention.
  • malignancies which are sensitive to treatment with IL-2, such as malignant melanomas, will be suitable targets for treatment with thioredoxin, suitably in combination with a co-factor.
  • T-cells and NK-cells can be strengthened by treatment with thioredoxin, optionally in combination with a co-factor as described.
  • thioredoxin, co-factors or combinations thereof are administered in a manner which is analogous with known ways of administering medicaments for the treatment of cancer.
  • administration will preferably be made by infusion or by intramuscular deposition.
  • the amount in which thioredoxin and/or co-factors is administered will vary within a wide range and will depend on various circumstances such as the severity of the disease and the age and the state of the patient.
  • a suitable dosage interval can be mentioned a dosage which will provide a serum or plasma level of thioredoxin which is from about 2 to about 100 times the naturally occurring thioredoxin serum or plasma level.
  • the following Table 1 gives a list which exemplifies co- factors which may be used.
  • the designation E indicates that the co-factor mainly is experimental and has possible use for diagnostic purposes.
  • the designation C indicates that the co-factor has clinical use.
  • BSF1 C Interleukin 4 (BSF1) C Anti-IL4-receptor antibodies
  • CDllc C C3d receptor (CDllc) reactive agents C and anti- receptor (gp 140) antibodies
  • Vitamins in particular vitamin A, D, and biologically active derivatives
  • the enzyme thioredoxin as used in the present invention is preferably of human origin. It is an enzyme catalyzing thiol-disulphide interchange reactions and net protein disulphide reductions via Cys-Gly-Pro-Cys active site.
  • Human thioredoxin is preferably of human lymphocyte origin although other origins can be used. However, also the use of animal including mammal thioredoxin, procaryotic thioredoxin obtained e.g. from E. Coli and thioredoxins produced by genetically engineered expression vectors is included in the scope of the invention.
  • Thioredoxin also known as thiol-oxidoreductase, is a ubiquitous 12 kDa protein with a redox-active disulphide (3); it is usually reduced by N-ADPH and the flavoprotein thioredoxin reductase. Reduced thioredoxin is a hydrogen donor for ribonucleotide reductase, an essential enzyme making deoxyribonucleotides for DNA synthesis. Thioredoxin is also involved in regulatory events (3), such as the light-dependent activation of photo-synthetic enzymes in the chloroplast of plant cells (4), and activation of glucocorticoid receptors to a steroid binding state (5).
  • regulatory events (3) such as the light-dependent activation of photo-synthetic enzymes in the chloroplast of plant cells (4), and activation of glucocorticoid receptors to a steroid binding state (5).
  • Mammalian thioredoxins have been isolated and characterized (3,6). The distribution has been studied by immunohistochemical methods and thioredoxin was shown to be related to protein secretion and partly membrane associated (6) .
  • thioredoxin was reported to be an IL-1 like factor, derived from an Epstein-Barr virus containing B-cell line (7).
  • Tagaya and co-workers (8) showed that the IL-2-receptor/Tac-inducing factor, also called adult T cell leukemia (HTLV-1) derived factor (ADF), was homologous to or identical with thioredoxin from analysis of a c-DNA clone.
  • HTLV-1-1 adult T cell leukemia
  • SUBSTITUTESHEET The present invention assigns new biological functions for the thioredoxin family of enzymes and expands its role in lymphocyte activation.
  • Target cells in clinical situations are all such malignantly transformed cells that can respond to thioredoxin, especially MP6/Trx, by differentiation, including all those malignant cells that can be induced to express binding sites for thioredoxin and respond to this.
  • Such induction can be exerted by the co-factors described in Table 1 or by other means.
  • the MP6 is a CD4 "1" T helper cell hybridoma, previously isolated and cloned by us (9).
  • the MP6 clone constitutively secretes as 12-14 kDa B cell stimulatory factor (BSF-MP6) inducing proliferation and IgM/IgG secretion in normal (9, 10), as well as in malignant pre- activated B cells of B-type chronic lymphocytic leukemia (B-CLL) (11).
  • BSF-MP6 B cell stimulatory factor
  • the IL-2 receptor expression was also enhanced by BSF-MP6 (12). Kishimoto and Honjo et al. have demonstrated that mR A from MP6 cells did not hybridize with cDNA probes for IL-l ⁇ , IL-1B, IL-4, IL-5 nor IL-6 (12).
  • the MP6 supernatant was shown to lack activities of LMW-BCGF, TNF- ⁇ , and - ⁇ , IFN- ⁇ , - ⁇ , - ?*, granulocyte-monocyte colony stimulating factors (GM-CSF), IL-1, IL-2, IL-4, IL-5 and IL-6 (9).
  • GM-CSF granulocyte-monocyte colony stimulating factors
  • _7 signals, or by a sub-optimal dose of TPA (1.6x10 M) for 1 h.
  • the cells were refractory to any of the re ⁇ ombinant or natural B-lymphotropic lymphokines rIL-l ⁇ , rIL-2, rIL-4, rIL-6, rTNF ⁇ , LMW-BCGF, rlFN- ⁇ , anti-CD40, or combinations thereof.
  • SAC-activated cells did, however, respond to the lymphokines rIL-2, rTNF ⁇ , LMW-BCGF, when BSF-MP6, was added (Figure 1A) .
  • TPA provides a non- physiological signal directly activating proteinkinase C, moving the cells into the cell cycle.
  • Figure IB illustrates that TPA activated cells responded to BSF-MP6 alone, and that the combinations of BSF-MP6 with several
  • Serum-free medium of 24h conditioned medium MP6 contained 34 ng/ml of thioredoxin.
  • Biological activity was monitored using the 183 B-CLL clone or normal tonsillar B cells and was confined to the 12 kDa region in gelfiltration experiments.
  • Mammalian thioredoxins after air oxidation, forms extra structural intra-molecular disulphide bonds leading to inactivation and aggregation (6) .
  • preparations of BSF- MP6 were also easily oxidized, by atmospheric 0-, with a resulting loss of activity.
  • the B-CLL cells were pre-treated with SAC 1:100 000 and IL 2 10 U/ml. 3H-Thy was added for the last 18h of a 72h incubation period. As is seen in Table 2, the thioredoxin was highly active.
  • BSF- MP6/thioredoxin is according to the evidence presented here one of the missing links.
  • T helper lymphocytes in B-CLL patients (15) might result in a loss of thioredoxin production, necessary for the activation of the B-CLL cells, as shown by our results.
  • the B-CLL cells themselves might be deficient for autocrine thioredoxin or require an initial dose of externally supplied thioredoxin to initiate its autocrine production.
  • B-iymphotropic herpesvirus Epstein-Barr virus EBV
  • the B-CLL cells have, however, been refractory to attempts of EBV-transformation and one possible explanation to this resistance could be found in the fact that B-CLL cells, in addition to their low expression of
  • SUBSTITUTESHEET EBV-receptors might be defective in their thioredoxin gene expression as indicated in this report and by our preliminary immunofluorescence analysis.
  • Cellular thioredoxin was recently suggested to be a principal hydrogen donor for herpes virus simplex-type 1 encoded ribonucleotide reductase (18).
  • thioredoxin in the B-CLL cells could effectively block an herpesvirus multiplication in those cells.
  • Thioredoxin plus compounds in Table 1 should be administered in combination when the malignant cells do not express any of the binding sites for thioredoxin. This includes any of the specific compounds listed.
  • MP6 was obtained from serum-free 24 h cultures of the MP6 T cell hybridoma grown in Iscoves medium supplemented with 400 ⁇ g/ml of BSA (Boerhinger-Mannheim, Mannheim, W.Germany), 12.5 ⁇ g/ml of human transferrin (Kabi, Sweden), 50 ⁇ M ⁇ -mercaptoethanol, 2mM L-
  • rIL-2 was purchased from Amgen (Amersham, Amersham, G.B. ) .
  • rIL-l ⁇ (Genzyme, Boston, MA) had a specific activity of 10 8 U/mg and was used at 10 U/ml.
  • rIL-4 was purchased from Genzyme (Boston, MA) and used at a final concentration of lOOU/ml.
  • rIL6 was a gift from Dr. Kishimoto, Osaka, Japan, and was used at 100 U/ml.
  • Recombinant TNF ⁇ with a specific activity of 6 x 10 "7 U/mg was used at 100 ng/ml and was a gift from Dr. G.R.
  • LMW-BCGF was purchased from Cellular Products (Buffalo, NY) was used at a concentration of 10% v/v.
  • rIFN-j- was obtained from Genentech (San Fransisco, CA) . It had a specific activity of 3 x 10 7 U/mg and was used at 500 U/ml.
  • Radioimmunoassay for thioredoxin shows identity between BSF-MP6 and thioredoxin.
  • Solid line indicates pure human placenta thioredoxin.
  • Broken line indicates BSF-MP6.
  • the radioimmunoassay was performed as described previously (13), briefly: 0.1 ml (0.2 pmol) of " ⁇ -labeled human placenta thioredoxin was incubated with 0.1 ml of standard human thioredoxin or unkonwn sample (MP6 supernatant concentrated 50-fold by ammonium sulphate precipitation) , serialy diluted, and 0.1 ml (5 ⁇ g) of the IgG fraction of a rabbit antiserum against human thioredoxin, at 37° C with shaking for 4 hours.
  • BSF-MP6 activity by reduction with DTT.
  • the biological activity of BSF-MP6 could be recovered by reduction as shown above.
  • the thioredoxin-expressing T- hybridoma clone MP6 was cultured for 24 hours in Iscoves medium containing 400 ⁇ g/ml of BSA, 12.5 ⁇ g/ml of human transferrin, 50 ⁇ M ⁇ -mercaptoethanol, 100 ⁇ g/ml of streptavidin, and 100 U/ml of penicillin and 2nM of L- glutamin, but the biological activity of the supernatant was lost after two weeks of storage at +4°C.
  • Phast gel system was used for analysis of the purity.
  • the samples are from left to right: MP6 serum free supernatant, before the affinity column; Affinity purified BSF-MP6/Thioredoxin; Human placenta thioredoxin; Molecular weight markers (Pharmacia) from top to bottom: 92.5 kDa, 67 kDa, 45 kDa, 30.1 kDa, 20.1 kDa, 14.7 kDa.
  • IL-5 C. Azuma et al.. Nucleic Acid Res. 14. 9149 (1986);
  • IL-6 T. Hirano et al.. Nature 234, 73 (1986);
  • LMW-BCGF S. Sharma, S. Mehta, J. Morgan, and A.
  • IFN-V D.V. Goeddel et al., Nature 287, 411, (1980); Lymphotoxin (TNF- ⁇ ): P.W. Gray, Nature 312, 712,
  • TNF T. Shirai, H. Yamaguchi, H. Ito, C. W. Todd, and

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP90913906A 1989-09-12 1990-09-10 Verwendung von thioredoxin in der behandlung bösartig transformierter zellen bei tieren und beim menschen Withdrawn EP0489113A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use
SE8903003 1989-09-12

Publications (1)

Publication Number Publication Date
EP0489113A1 true EP0489113A1 (de) 1992-06-10

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90913906A Withdrawn EP0489113A1 (de) 1989-09-12 1990-09-10 Verwendung von thioredoxin in der behandlung bösartig transformierter zellen bei tieren und beim menschen

Country Status (12)

Country Link
EP (1) EP0489113A1 (de)
JP (1) JPH05500216A (de)
AU (1) AU641942B2 (de)
CA (1) CA2065454A1 (de)
DD (1) DD298056A5 (de)
FI (1) FI921058A0 (de)
GR (1) GR1001151B (de)
HU (1) HUT62932A (de)
IE (1) IE903233A1 (de)
PT (1) PT95284A (de)
SE (1) SE8903003D0 (de)
WO (1) WO1991004320A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
AU3643497A (en) * 1996-06-28 1998-01-21 National Jewish Center For Immunology And Respiratory Medicine Use of thioredoxin-like molecules for induction of mnsod to treat oxidative damage
EP0946192A1 (de) * 1996-12-06 1999-10-06 Garth Powis Verwendung von thioredoxin
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
WO1999038963A1 (en) 1998-01-30 1999-08-05 Genesense Technologies, Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
CA2340091C (en) 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
EP1131093A4 (de) 1998-11-09 2002-05-02 Idec Pharma Corp Behandlung hämatologischer bösartigkeiten assoziiert mit zirkulierenden tumorzellen unter verwendung chimärer anti-cd20 antikörper
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1332212A2 (de) * 2000-08-25 2003-08-06 Curagen Corporation Proteine und dafür kodierende nukleinsäuren
CA2498581C (en) 2002-09-10 2019-03-19 National Jewish Medical And Research Center Thioredoxin composition and uses thereof for liquefaction of mucus or sputum
US9168290B2 (en) 2013-03-15 2015-10-27 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (ja) * 1987-06-12 1997-07-23 味の素株式会社 ヒトａｄｆをコードする遺伝子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9104320A1 *

Also Published As

Publication number Publication date
WO1991004320A1 (en) 1991-04-04
HU9200821D0 (en) 1992-05-28
HUT62932A (en) 1993-06-28
FI921058A7 (fi) 1992-03-11
AU6433690A (en) 1991-04-18
SE8903003D0 (sv) 1989-09-12
IE903233A1 (en) 1991-03-27
JPH05500216A (ja) 1993-01-21
FI921058A0 (fi) 1992-03-11
PT95284A (pt) 1991-08-14
CA2065454A1 (en) 1991-03-13
GR1001151B (el) 1993-05-24
DD298056A5 (de) 1992-02-06
GR900100679A (en) 1992-01-20
AU641942B2 (en) 1993-10-07

Similar Documents

Publication Publication Date Title
Defrance et al. Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes.
Rosén et al. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin
AU641942B2 (en) The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
Lotz et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.
Schmouder et al. In vitro and in vivo interleukin-8 production in human renal cortical epithelia
Schluesener Transforming growth factors type β1 and β2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-γ and tumor necrosis factor-α
Petit-Frere et al. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes
Ceuppens et al. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal.
Bertagnolli et al. IL-12 augments antigen-dependent proliferation of activated T lymphocytes
Schmitt et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma.
Defrance et al. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.
DeKruyff et al. Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor.
Defrance et al. Human interferon-gamma acts as a B cell growth factor in the anti-IgM antibody co-stimulatory assay but has no direct B cell differentiation activity.
JPH09510444A (ja) 自己免疫疾患の治療におけるｉｌ−１２およびｉｌ−１２アンタゴニストの使用
Ke et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Te Velde et al. IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes.
Link et al. Transforming growth factor-β1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis
EP0305468A1 (de) B-Zellen-Wachstums- und Differenzierungsfaktor BCGF 12K zur Verwendung in der Therapie
Jurado et al. The immunomodulatory effects of interferon-gamma on mature B-lymphocyte responses
Sleasman et al. The role of functionally distinct helper T lymphocyte subpopulations in the inductionof human B cell differentiation
Grimm et al. The IL‐2 mediated amplification of cellular cytotoxicity
Moqattash et al. Leukemia cells and the cytokine network
Wilson et al. Interleukin-2-induced production of interferon-γ by resting human T cells and large granular lymphocytes: requirement for accessory cell factors, including interleukin-1
Mossalayi et al. Early human thymocyte proliferation is regulated by an externally controlled autocrine transforming growth factor-beta 1 mechanism

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940615